BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease. We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients. METHODS: Sixty-four chemoresistant HL patients underwent HDT followed by ASCT at our center. Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%). Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning. RESULTS: The estimated 5-year overall survival (OS) and progression-free survival (PFS) were 31% and 17%, respectively (median follow-up = 4.2 years). Multivariate analysis only identified year of transplant as independently associated with improved OS (P = .008) and PFS (P = .04), with patients receiving transplants in later years having better outcome. The probabilities of 3-year PFS for patients receiving transplants during 1986 to 1989, 1990 to July 1993, August 1993 to 1999, and 2000 to 2005 were 9%, 21%, 33%, and 31%, respectively. CONCLUSIONS: These data suggest that HDT and ASCT may result in prolonged remissions and survival for a subset of chemoresistant HL patients, with improved outcomes in patients receiving transplants more recently. (c) 2008 American Cancer Society.
BACKGROUND: High-dose therapy (HDT) with autologous stem cell transplantation (ASCT) is the standard treatment for patients with chemosensitive relapsed/refractory Hodgkin lymphoma (HL), but this therapy is commonly denied to patients with resistant disease. We explored the utility of HDT and ASCT for chemoresistant HL because there are few established therapies for these patients. METHODS: Sixty-four chemoresistant HL patients underwent HDT followed by ASCT at our center. Baseline characteristics included median age = 35 years (range, 14-59 years), stage III/IV = 49 (77%), nodular sclerosis histology = 51 (80%), and prior radiation = 32 (50%). Twenty-six patients (41%) received total body irradiation (TBI)-based regimens, and 38 (59%) underwent non-TBI conditioning. RESULTS: The estimated 5-year overall survival (OS) and progression-free survival (PFS) were 31% and 17%, respectively (median follow-up = 4.2 years). Multivariate analysis only identified year of transplant as independently associated with improved OS (P = .008) and PFS (P = .04), with patients receiving transplants in later years having better outcome. The probabilities of 3-year PFS for patients receiving transplants during 1986 to 1989, 1990 to July 1993, August 1993 to 1999, and 2000 to 2005 were 9%, 21%, 33%, and 31%, respectively. CONCLUSIONS: These data suggest that HDT and ASCT may result in prolonged remissions and survival for a subset of chemoresistant HL patients, with improved outcomes in patients receiving transplants more recently. (c) 2008 American Cancer Society.
Authors: A Josting; I Kàtay; U Rueffer; S Winter; H Tesch; A Engert; V Diehl; P D Wickramanayake Journal: Ann Oncol Date: 1998-03 Impact factor: 32.976
Authors: A Nademanee; M R O'Donnell; D S Snyder; G M Schmidt; P M Parker; A S Stein; E P Smith; A Molina; D E Stepan; G Somlo Journal: Blood Date: 1995-03-01 Impact factor: 22.113
Authors: D C Linch; D Winfield; A H Goldstone; D Moir; B Hancock; A McMillan; R Chopra; D Milligan; G V Hudson Journal: Lancet Date: 1993-04-24 Impact factor: 79.321
Authors: J W Sweetenham; G Taghipour; D Milligan; A K Blystad; D Caballero; A Fassas; A H Goldstone Journal: Bone Marrow Transplant Date: 1997-11 Impact factor: 5.483
Authors: S J Horning; N J Chao; R S Negrin; R T Hoppe; G D Long; W W Hu; R M Wong; B W Brown; K G Blume Journal: Blood Date: 1997-02-01 Impact factor: 22.113
Authors: L Voillat; E Deconinck; M Flesch; A Brion; A Rozenbaum; J Vuillier; J J Pavy; R Angonin; J P Carbillet; P Hervé Journal: Nouv Rev Fr Hematol Date: 1994-12
Authors: M Crump; A M Smith; J Brandwein; F Couture; H Sherret; D M Sutton; J G Scott; J McCrae; C Murray; D Pantalony Journal: J Clin Oncol Date: 1993-04 Impact factor: 44.544
Authors: Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett Journal: Nat Rev Dis Primers Date: 2020-07-23 Impact factor: 52.329
Authors: Ajay K Gopal; Radhakrishnan Ramchandren; Owen A O'Connor; Robert B Berryman; Ranjana H Advani; Robert Chen; Scott E Smith; Maureen Cooper; Achim Rothe; Jeffrey V Matous; Laurie E Grove; Jasmine Zain Journal: Blood Date: 2012-04-17 Impact factor: 22.113
Authors: A Raiola; A Dominietto; R Varaldo; A Ghiso; F Galaverna; S Bramanti; E Todisco; B Sarina; L Giordano; A Ibatici; A Santoro; M Clavio; A Bacigalupo; L Castagna Journal: Bone Marrow Transplant Date: 2013-11-04 Impact factor: 5.483
Authors: L Hegerova; Q Cao; A Lazaryan; B L McClune; D J Weisdorf; C G Brunstein; V Bachanova Journal: Bone Marrow Transplant Date: 2017-01-30 Impact factor: 5.483